Nathan P. Lawrence
Plus aucun poste en cours
Fortune : 44 $ au 30/04/2024
Profil
Nathan P.
Lawrence worked as a Director of Research & Development at Boston Biomedical, Inc. and as a Vice President of Sales & Marketing at Pressure BioSciences, Inc. Lawrence holds a doctorate degree from Yale University, a graduate degree from Southern Connecticut State University, and an undergraduate degree from the University of Miami.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/07/2012 | 200 ( 0,14% ) | 44 $ | 30/04/2024 |
Anciens postes connus de Nathan P. Lawrence
| Sociétés | Poste | Fin |
|---|---|---|
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Directeur Technique/Scientifique/R&D | - |
| PRESSURE BIOSCIENCES, INC. | Sales & Marketing | - |
Formation de Nathan P. Lawrence
| University of Miami | Undergraduate Degree |
| Southern Connecticut State University | Graduate Degree |
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PRESSURE BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
